NEW YORK (GenomeWeb News) — Cambridge BioScience today said it will distribute and support Chan Test’s potassium channel assays in Europe.
 
Cleveland-based Chan Test’s assay, based on ion channels, is designed to predict cardiac events associated with non-cardiac drugs.
 
Cambridge BioScience Managing Director Mike Kerns said his company expects “significant growth” for the assay due to “the rapidly growing interest in ion channels as primary targets in areas such as pain and epilepsy research.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.